Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (605)	1/30/2002 9:51:53 AM
From: tuck	Read Replies (1) \| Respond to of 1005

BLUE HP buys 1000 more PDGM @$2.65. Cheers, Tuck

To: tuck who wrote (605)	1/31/2002 10:09:25 AM
From: tuck	Read Replies (1) \| Respond to of 1005

The nice thing about migraine trials is that they're really fast . . . >>CHAPEL HILL, N.C., Jan. 31 /PRNewswire-FirstCall/ -- POZEN Inc. (Nasdaq: POZN - news), a pharmaceutical development company with a portfolio of candidates for the treatment of migraine, today announced that it has commenced the second and final planned Phase III pivotal trial for approval of MT 300, the company's injectable product candidate for the treatment of severe migraine. POZEN expects to complete this trial in the clinic during the second quarter and that data should be available during the third quarter. MT 300 is a new, improved formulation of DHE in a convenient, pre-filled syringe that is suitable for at-home use. This double-blind and placebo- controlled trial will treat 400 patients, who suffer from acute migraine, at 30 centers in the United States. It is designed to compare the efficacy of MT 300 to placebo, with sustained pain response as the primary endpoint and nausea and sensitivity to light and sound as secondary endpoints. MT 300's initial Phase III pivotal trial is expected to be completed in the clinic during the first quarter 2002, with data available in the second quarter. A total of 600 patients from 30 U.S. centers will be treated in this double-blind, placebo-controlled trial. The trial's primary endpoint is sustained pain response, with nausea and sensitivity to light and sound as secondary endpoints. John R. Plachetka, Pharm.D., POZEN's chairman, president and chief executive officer, said, ``One of our stated goals for 2002 was to commence this trial in the first quarter, and we based our other milestones for MT 300 on achieving this goal. By meeting this deadline, our development timeline, including filing a New Drug Application by the end of this year, remains on schedule.''<< snip Cheers, Tuck